Clinical Issues and Treatment of Lung Cancer in Mexico


  • Rufino Echegoyen-Carmona Lung Oncology, National Respiratory Diseases Institute (INER), Mexico City
  • Daniel Mendoza-Posada Lung Oncology, National Respiratory Diseases Institute (INER), Mexico City
  • Catalina Camacho-Mendoza Lung Oncology, National Respiratory Diseases Institute (INER), Mexico City
  • Oswaldo Rafael Sánchez-Campos Lung Oncology, National Respiratory Diseases Institute (INER), Mexico City



Metastasis, median overall survive, adyuvant chemotherapy


 Retrospective analysis of 101 lung cancer patients treated at the INER [National Respiratory Diseases Institute] in Mexico from January 2006 to October 2007. Objective: Analysis of clinical situation and treatment. Results: The study comprised 59 men and 42 women: 58 % > 60 years old. 14.8% were non-smokers or had no smoking history. 85.2% were heavy smokers with a smoking history above15 packs per year. Eleven patients had one family member with cancer. 86.1% of them were admitted to hospital when the tumor stage was between IIIA and IV. 21 patients of this group had metastasis. 86.1% had an ECOG grade of 0.2. Two analytical parameters were handled: RECIST and the media overall survival. 93 of 101 patients (92%) were treated with chemotherapy: 51 of them (54.7%) with Cisplatine and Paclitaxel, 29 (31.1%) with Cisplatine and Vinorrelbine, and 13 (13.8%) with Cisplatine and Gemcitabine, each one for 2 to 6 cycles. According to RECIST, 6 patients had a complete response, 19 had progressions with distal metastasis, and 68 had partial responses. The median overall survival was of 17.0, 18.4, and 16.1months, respectively. Chirurgic intervention was carried out in 8 patients, lobectomy in 7 patients, and one had a pneumonectomy with resection of mediastinal lymph nodes and adyuvant chemotherapy. Histopathology of the lymph nodes and bronchial section were negative for neoplasia. The disease-free survival was 13 to 25 months in lobectomies and 22 months in the pneumonectomy. The cause of dead could not be specified because they did not continue attending post-treatment control. Conclusion: Lack of Health Education amongst patients and their families was found to be a major cause which prevented a more effective result of the treatment. This study also concludes that a multidisciplinary treatment for lung cancer patients is required.


Meerbeeck J, Surmont V. Stage IIIA-N2 NSCLC: A review of its treatment approaches and future developments. Lung Cancer 2009; 65: 257-67.

Medina MF, Barrera RR, Morales JF, Echegoyen CR, Chavarría JG, et al. Primary lung cancer in Mexico City: a report of 1019 cases. Lung Cancer 1996; 14: 155-93.

Ruíz GL, Rizo RP, Sánchez CF, Osornio VA, García CC, et al. Mortality due to lung cancer in Mexico. Lung Cancer 2007; 58: 184-90.

Instituto Nacional de Estadística, Geografía e Informática, México (INEGI) Reporte sobre morbilidad y mortalidad en México 2004-2007.

Rivera MP, Mehta AC. Initial Diagnosis of lung Cancer: ACCP Evidence-based clinical practice guidelines 2nd ed. Chest 2007; 132: 131S-148S.

Giroux LE, Lavole A, Ruppert AM, Gounant V, Wislez MM, et al. Factors associated with long-term survival of patients with advanced non small cell lung cancer. Respirology 2011; 17: 134-43.

Therasse P, Arbuck SG, Eisenhauer E, Wanders J, Kaplan RS, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-16.

Miller AB, Hoogstraten MD, Staquet M, Winkler MD. Reportin Results of cancer treatment. Cancer 1981; 47: 207-14.<207::AID-CNCR2820470134>3.0.CO;2-6

Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Grup. J Clin Oncol 2008; 26(21): 3552-9.

Azzoli Ch, Baker S, Temin S, et al. American Society of Clinical Oncology. Practice Guideline Update on Chemotherapy for Stage IV Non. Small Cell Lung Cancer. J Clin Oncol 2009; 27: 6251-66.

Thatcher N, Heighway J. Maintenance and consolidation therapy in patients with unresectable stage III/IV non-small cell lung cancer. Oncologist 2010; 15: 1034-43.

D’Addario G, Pintilie M, Leighl NB, Feld R, Cerny T, et al. Platinum-based versus non-platinum based chemotherapy in advanced non-small cell lung cancer: a meta-analysis of the published literature. J Clin Oncol 2005; 23(13): 2926-36.

Pisters K, Evans W, Azzoli C, Kris M, Smith CA, et al. Cancer care Ontario and American society of clinical oncology adyuvant chemotherapy and adyuvant radiation therapy for stages I-IIIA resectable non-small-cell lung cancer guideline. J Clin Oncol 2007; 25(34): 5506-18.

Rena O, Carsana L, Cristina S, Papalia E, Massera F, Lymph node isolated tumor cells and micrometastases in pathological stage I non-small cell lung cancer: prognostic significance. Eur J Cardiothorac Surg 2007; 32(6): 863-7.

Zhonga W, Yanga X, Baib J, Yanga J, Manegolc C, et al. Complete mediastinal lymphadenectomy: the core component of the multidisciplinary therapy in resectable non-small cell lung cancer. Eur J Cardiothorac Surg 2008; 34(1): 187-95.

Herpel E, Muley T, Schneider T, et al. A pragmatic approach to the diagnosis of nodal micrometastasis in early non-small cell lung cancer. J Thorac Oncol 2010; 5(8): 1206-12.

Le Chevalier T, Arriagada R, Pignon JP, Scagliotti GV. Should adyuvant chemotherapy become standard treatment in all patients with resected non-small cell lung cancer? Lancet Oncol 2005; 6(3): 182-4.

Belcher, Goldstraw P. Is radical mediastinal dissection mandatory for curative resection of NSCLC? Eur J Cardiothorac Surg 2007; 31(1): 142-3.




How to Cite

Rufino Echegoyen-Carmona, Daniel Mendoza-Posada, Catalina Camacho-Mendoza, & Oswaldo Rafael Sánchez-Campos. (2012). Clinical Issues and Treatment of Lung Cancer in Mexico . Journal of Analytical Oncology, 1(1), 62–66.